Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Ann Pharmacother ; 54(7): 669-675, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-31893932

RESUMEN

Background: Current guidelines from the American College of Obstetricians and Gynecologists recommend insulin as the standard therapy for treatment of pregestational and gestational diabetes (PGDM and GDM). However, the guidelines do not specify which type(s) of insulin to utilize. Additionally, there are limited published data regarding safety parameters of insulin in this population. Objective: To evaluate if insulin glargine or detemir (long-acting insulin) results in less hypoglycemia, hospitalizations, or delivery complications compared with intermediate-acting insulin neutral protamine Hagedorn (NPH) in PGDM and GDM. Methods: This single-center, retrospective, observational cohort study included pregnant women who were 18 years or older with PGDM or GDM and received insulin therapy during pregnancy at an outpatient obstetric clinic. The primary outcome was the frequency of hypoglycemia (BG < 60 mg/dL). Secondary outcomes included emergency department visits and hospitalizations, delivery complications, and the duration of time at glycemic targets during pregnancy. Results: A total of 63 patients were included for evaluation. There was no significant difference in the frequency of hypoglycemia between the long-acting and NPH groups (4.4 vs 6.2 events per patient, respectively; P = 0.361). Patients receiving long-acting insulin had significantly more encounters with diabetes education (10.6 vs 5.1 visits per patient, P = 0.002) and more consistently provided glucose readings at their appointments (8.3 vs 4.8, P = 0.043). There was no difference in hospitalizations or maternal and neonatal complications. Conclusion and Relevance: Long-acting insulins did not reduce the frequency of hypoglycemia compared with NPH. The results of this study confirm the need for additional investigations with larger populations.


Asunto(s)
Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Gestacional/tratamiento farmacológico , Hipoglucemia/inducido químicamente , Hipoglucemiantes/efectos adversos , Insulina Detemir/efectos adversos , Insulina Glargina/efectos adversos , Insulina Isófana/efectos adversos , Adulto , Glucemia/análisis , Estudios de Cohortes , Femenino , Humanos , Hipoglucemia/epidemiología , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/uso terapéutico , Insulina Detemir/administración & dosificación , Insulina Detemir/uso terapéutico , Insulina Glargina/administración & dosificación , Insulina Glargina/uso terapéutico , Insulina Isófana/administración & dosificación , Insulina Isófana/uso terapéutico , Masculino , Embarazo , Estudios Retrospectivos , Resultado del Tratamiento , Adulto Joven
2.
Placenta ; 52: 17-20, 2017 04.
Artículo en Inglés | MEDLINE | ID: mdl-28454693

RESUMEN

Immortalization of primary cells with telomerase is thought to maintain normal phenotypic properties and avoid chromosomal abnormalities and other cancer-associated changes that occur following simian virus 40 tumor antigen (SV40 Tag) induced immortalization. However, we report that the human telomerase reverse transcriptase (hTERT)-immortalized SWAN-71 trophoblast cell line has a near pentaploid 103∼119,XXXX[cp20] karyotype. Additionally, DNA typing analysis indicated that SWAN-71 cells have acquired microsatellite instability. In comparison, the post-crisis SV40-transformed trophoblast cell line 3A-subE was hypertriploid 69∼81,XX[cp20]. Both cell lines contained multiple specific clonal rearrangements. These findings emphasize the need to monitor for genetic instability in hTERT-immortalized cells.


Asunto(s)
Cariotipo , Inestabilidad de Microsatélites , Trofoblastos/citología , Línea Celular , Citogenética , Humanos , Trofoblastos/metabolismo
3.
Matern Child Health J ; 21(2): 297-305, 2017 02.
Artículo en Inglés | MEDLINE | ID: mdl-27423239

RESUMEN

Objective To determine the impact of Centering Pregnancy©-based group prenatal care for Hispanic gravid diabetics on pregnancy outcomes and postpartum follow-up care compared to those receiving traditional prenatal care. Methods A cohort study was performed including 460 women diagnosed with gestational diabetes mellitus (GDM) who received traditional or Centering Pregnancy© prenatal care. The primary outcome measured was completion of postpartum glucose tolerance testing. Secondary outcomes included postpartum visit attendance, birth outcomes, breastfeeding, and initiation of a family planning method. Results 203 women received Centering Pregnancy© group prenatal care and 257 received traditional individual prenatal care. Women receiving Centering Pregnancy© prenatal care were more likely to complete postpartum glucose tolerance testing than those receiving traditional prenatal care, (83.6 vs. 60.7 %, respectively; p < 0.001), had a higher rate of breastfeeding initiation (91.0 vs. 69.4 %; p < 0.001), had higher rates of strictly breastfeeding at their postpartum visit (63.1 vs. 46.3 %; p = 0.04), were less likely to need medical drug therapy compared to traditional prenatal care (30.2 vs. 42.1 %; p = 0.009), and were less likely to undergo inductions of labor (34.5 vs. 46.2 %; p = 0.014). When only Hispanic women were compared, women in the Centering group continued to have higher rates of breastfeeding and completion of postpartum diabetes screening. Conclusion for Practice Hispanic women with GDM who participate in Centering Pregnancy© group prenatal care may have improved outcomes.


Asunto(s)
Diabetes Gestacional/terapia , Hispánicos o Latinos/psicología , Evaluación del Resultado de la Atención al Paciente , Atención Prenatal/métodos , Atención Prenatal/normas , Adulto , Lactancia Materna/etnología , Lactancia Materna/estadística & datos numéricos , Estudios de Cohortes , Diabetes Gestacional/etnología , Diabetes Gestacional/psicología , Femenino , Prueba de Tolerancia a la Glucosa/estadística & datos numéricos , Hispánicos o Latinos/estadística & datos numéricos , Humanos , Embarazo , Estudios Retrospectivos
4.
Pediatr Res ; 75(2): 266-72, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24232636

RESUMEN

BACKGROUND: Children born to mothers with gestational diabetes mellitus (GDM) experience increased risk of developing hypertension, type 2 diabetes mellitus, and obesity. Disrupted function of endothelial colony-forming cells (ECFCs) may contribute to this enhanced risk. The goal of this study was to determine whether cord blood ECFCs from GDM pregnancies exhibit altered functionality. METHODS: ECFCs isolated from the cord blood of control and GDM pregnancies were assessed for proliferation, senescence, and Matrigel network formation. The requirement for p38MAPK in hyperglycemia-induced senescence was determined using inhibition and overexpression studies. RESULTS: GDM-exposed ECFCs were more proliferative than control ECFCs. However, GDM-exposed ECFCs exhibited decreased network-forming ability in Matrigel. Aging of ECFCs by serial passaging led to increased senescence and reduced proliferation of GDM-exposed ECFCs. ECFCs from GDM pregnancies were resistant to hyperglycemia-induced senescence compared with those from controls. In response to hyperglycemia, control ECFCs activated p38MAPK, which was required for hyperglycemia-induced senescence. In contrast, GDM-exposed ECFCs showed no change in p38MAPK activation under equivalent conditions. CONCLUSION: Intrauterine exposure of ECFCs to GDM induces unique phenotypic alterations. The resistance of GDM-exposed ECFCs to hyperglycemia-induced senescence and decreased p38MAPK activation suggest that these progenitor cells have undergone changes that induce tolerance to a hyperglycemic environment.


Asunto(s)
Diabetes Gestacional/sangre , Células Endoteliales/citología , Sangre Fetal/citología , Adulto , Proliferación Celular , Senescencia Celular , Colágeno/química , Combinación de Medicamentos , Activación Enzimática , Femenino , Humanos , Hiperglucemia/metabolismo , Hiperglucemia/fisiopatología , Recién Nacido , Laminina/química , Masculino , Intercambio Materno-Fetal , Embarazo , Proteoglicanos/química , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA